Primary malignant ossifying fibromyxoid tumour of the bone. A clinicopathologic and molecular report of two cases

Malignant Ossifying Fibromyxoid Tumor of the Chest Wall Metastasized to the Lung Even After Complete Resectioning of the Primary Tumor - A Case Report and a Comprehensive Review

An ossifying fibromyxoid tumor is a soft tissue neoplasm with ambiguous differentiation and low metastatic potential. Most cases involve the lower extremities, followed by the trunk, the upper extremities, and the head and neck region. It mainly arises in 40-70 years of age, and men dominate the disease's gender distribution. In the described types of ossifying fibromyxoid tumors, there are three variants: one is benign (typical), the second is malignant, which carries the risk of disease recurrence or metastases, and the third is atypical, which does not meet the criteria of either typical or malignant. Here, we present an interesting case of a malignant ossifying fibromyxoid tumor of the chest wall that metastasized to the lungs even after complete resection of the primary tumor. A 64-year-old man had a 4.0 cm malignant ossifying fibromyxoid tumor in his chest wall two years ago, and at that time, the tumor was removed entirely. On pathology review, it was noted to have 20 mitotic figures per 50 high-power fields, but no actual grade was given. He was given postoperative radiation. His recent computed tomography (CT) chest with contrast showed a new right upper lung lobe nodule measuring 0.78 cm compared to the previous contrast-enhanced CT chest six months ago. It was worrisome for metastasis. F-18 FDG positron emission tomography scan revealed sub-centimetric pulmonary nodules in the right upper lobe. Right upper lobe lung biopsy showed spindle cell neoplasm morphologically consistent with the patient's known history of malignant ossifying fibromyxoid tumor. Biopsy demonstrated fragments of the bronchial wall and alveolated lung parenchyma with a focal spindle cell proliferation demonstrating a fibromyxoid matrix. The patient was referred to the oncologist for further management. In conclusion, aggressive malignant ossifying fibromyxoid tumors can be found in atypical locations, e.g., the chest wall. Therefore, early diagnosis is crucial because of the high chances of metastasis to distant organs (including the lung) even after complete resection of the primary tumor. Even in asymptomatic patients, it is necessary to complete long-term follow-up for recurrence and metastasis surveillance of ossifying fibromyxoid tumors. Early recognition of recurrence or metastasis can decrease morbidity and mortality and improve overall organ function and patient survival.

Ossifying fibromyxoid tumour with an unusually prominent central ossification harbouring EPC1-PHF1 gene fusion: A case report and literature review

Ossifying fibromyxoid tumour (OFMT) is a soft tissue neoplasm of uncertain differentiation, with potential for recurrences and metastases depending on the presence of atypical or malignant histological features. Most cases show an incomplete shell of mature bone in the periphery of the lesion. Recurrent PHF1 gene rearrangements were also recently reported in OFMTs, with the most common rearrangement involving a fusion to EP400. We report a case of a 75-year-old male that was diagnosed with an OFMT showing an unusually prominent central ossification. Further, this lesion also harboured the less commonly reported EPC1-PHF1 gene fusion, thus further characterising the morphological features that are associated with this molecular event in this entity. Differential diagnoses of lesions with prominent ossification and emerging molecular findings associated with this entity are discussed.

Primary sclerosing epithelioid fibrosarcoma of the spine: a single-institution experience

AIMS

To present our experience on spinal sclerosing epithelioid fibrosarcoma (SEF) and review the existing literature pertaining to SEF of the spine.

METHODS AND RESULTS

Six cases of spinal SEF were reviewed, and a literature search of all primary SEFs of the spine was performed. All tumours occurred in adults (median age, 41 years) and were located all along the spine, the lumbar vertebrae being the most commonly involved. All patients presented with pain that they had experienced for months. The mean tumour size at diagnosis was 52 mm. Five tumours showed a spectrum of microscopic features consistent with pure SEF, and one showed a hybrid morphology with areas of low-grade fibromyxoid sarcoma. All were diffusely and strongly positive for mucin 4. Two cases were initially misdiagnosed as epithelioid haemangioendothelioma and aggressive chondroblastoma. Fluorescence in-situ hybridisation showed rearrangements of either FUS or EWSR1 in four cases. Reverse transcription polymerase chain reaction showed the presence of FUS-CREB3L1 and EWSR1-CREB3L1 fusion transcripts in two cases and one case, respectively. Of five patients with follow-up data available, two developed one or more local recurrences and three patients had metastatic disease. Distant metastases were mainly to other osseous locations, followed by lungs and lymph nodes. At last follow-up, three patients had died of disease and one was alive with multiple metastases.

CONCLUSIONS

SEF is an aggressive sarcoma that can involve the spine. It is important to recognise the spine as the primary location of SEF, in order to avoid misdiagnosis as more common primary spinal neoplasms, which can impact on therapeutic approaches.